Evolet Profile
Key Indicators
- Authorised Capital ₹ 35.26 Cr
as on 27-06-2024
- Paid Up Capital ₹ 28.41 Cr
as on 27-06-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 11.60%
(FY 2023)
- Profit 8.54%
(FY 2023)
- Ebitda -13.43%
(FY 2023)
- Net Worth 0.44%
(FY 2023)
- Total Assets 0.38%
(FY 2023)
About Evolet
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 35.26 Cr and a paid-up capital of Rs 28.41 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Evolet Private Limited India is Prateek Talwar as COMPANY SECRETARY. Zafarkhon Mirzoev, Sadullo Abdulloev, and Khayrullo Avgonov serve as directors at the Company.
- CIN/LLPIN
U74999DL2017PTC316909
- Company No.
316909
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Evolet?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prateek Talwar  | Company Secretary | 20-May-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Zafarkhon Mirzoev  | Director | 28-Apr-2017 | Current |
| Sadullo Abdulloev | Director | 28-Apr-2017 | Current |
| Khayrullo Avgonov | Director | 01-May-2018 | Current |
Financial Performance of Evolet.
Evolet Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.6% increase. The company also saw a slight improvement in profitability, with a 8.54% increase in profit. The company's net worth moved up by a moderate rise of 0.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evolet?
In 2023, Evolet had a promoter holding of 72.93% and a public holding of 27.07%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Spey Medical Private LimitedActive 13 years 4 monthsZafarkhon Mirzoev and Sadullo Abdulloev are mutual person
Evolet Healthcare Private LimitedActive 13 years 10 monthsZafarkhon Mirzoev, Sadullo Abdulloev and 1 more are mutual person
Neo Universe Pharmaceuticals Private LimitedActive 9 years 8 monthsSadullo Abdulloev is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Evolet?
Unlock and access historical data on people associated with Evolet, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evolet, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evolet's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
